AI has quietly revolutionized the field of ophthalmology.While the concept of AI may evoke futuristic images of robots and ...

LENSAR, Inc. is rated a Strong Buy by the Quant system, Wall Street analysts, and me, due to its innovative cataract treatment technology and growing market share. The company’s ALLY Robotic ...

In a remarkable display of market confidence, LENSAR Inc. (LNSR) stock has achieved a new 52-week high, with shares trading at $9.25. This peak represents a significant milestone for the company, ...

The options are subject to the terms and conditions of LENSAR’s 2024 Employment Inducement Incentive Award Plan and a stock option agreement covering the grant. LENSAR is a commercial-stage medical ...

("LENSAR" or "the Company"), a global medical technology company focused on advanced laser solutions for the treatment of cataracts, today announced that the ALLY Adaptive Cataract Treatment ...

As of 1:15:38 PM EST. Market Open. ORLANDO, Fla., Jan. 02, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the ...

ORLANDO, Fla., Feb. 03, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR’s board of ...